

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF DR. LIU YONGJUN AS EXECUTIVE PRESIDENT AND PRESIDENT OF GLOBAL RESEARCH AND DEVELOPMENT

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that Dr. Liu Yongjun (“**Dr. Liu**”) has been appointed as the executive president and president of global research and development of the Group, responsible for, among other things, research and development, pipeline strategy and international business development of the Group.

As a globally renowned scientist in the fields of immunology, oncology and translational medicine, Dr. Liu has more than 30 years of experience in the biopharmaceutical industry. He has served as the head of research and development at several companies, including Innovent Biologics, Sanofi and AstraZeneca (MedImmune), and possesses extensive working experience in the research and development departments of internationally renowned scientific research institutes and leading global pharmaceutical companies.

In addition, Dr. Liu has remarkable achievements and rich experience in science research, having published over 260 papers in top academic journals such as *Nature* and *Science*, with over 94,000 citations. These studies provide a number of key targets for drug development in the fields of immunology and oncology, such as thymic stromal lymphopoietin (TSLP), OX40 (CD134), and plasmacytoid dendritic cells (pDCs), and have advanced preclinical research in multiple fields, facilitating many drug candidates progress from initial laboratory discoveries to clinical applications.

Dr. Liu received his bachelor’s degree in Medicine from the Bethune Medical University, China and Ph.D. degree in Immunology from the University of Birmingham, UK.

The Board would like to extend a warm welcome to Dr. Liu in joining the Group.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 9 September 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.